183 related articles for article (PubMed ID: 37927606)
1. Development of a novel human triculture model of non-alcoholic fatty liver disease and identification of berberine as ameliorating steatosis, oxidative stress and fibrosis.
Rafiei H; Yeung M; Kowalski S; Krystal G; Elisia I
Front Pharmacol; 2023; 14():1234300. PubMed ID: 37927606
[No Abstract] [Full Text] [Related]
2. Extracellular vesicles derived from fat-laden hepatocytes undergoing chemical hypoxia promote a pro-fibrotic phenotype in hepatic stellate cells.
Hernández A; Reyes D; Geng Y; Arab JP; Cabrera D; Sepulveda R; Solis N; Buist-Homan M; Arrese M; Moshage H
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165857. PubMed ID: 32512191
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease.
Tang Y; Bian Z; Zhao L; Liu Y; Liang S; Wang Q; Han X; Peng Y; Chen X; Shen L; Qiu D; Li Z; Ma X
Clin Exp Immunol; 2011 Nov; 166(2):281-90. PubMed ID: 21985374
[TBL] [Abstract][Full Text] [Related]
4. Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease.
Ganji SH; Kashyap ML; Kamanna VS
Metabolism; 2015 Sep; 64(9):982-90. PubMed ID: 26024755
[TBL] [Abstract][Full Text] [Related]
5. Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis.
Bhattacharya D; Basta B; Mato JM; Craig A; Fernández-Ramos D; Lopitz-Otsoa F; Tsvirkun D; Hayardeny L; Chandar V; Schwartz RE; Villanueva A; Friedman SL
JHEP Rep; 2021 Jun; 3(3):100237. PubMed ID: 34151243
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
[TBL] [Abstract][Full Text] [Related]
7. Neferine ameliorates nonalcoholic steatohepatitis through regulating AMPK pathway.
Wang MY; Zhang SS; An MF; Xia YF; Fan MS; Sun ZR; Zhang LJ; Zhao YL; Sheng J; Wang XJ
Phytomedicine; 2023 Jun; 114():154798. PubMed ID: 37031639
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory Protein Signatures as Predictive Disease-Specific Markers for Non-Alcoholic Steatohepatitis (NASH).
Mounika N; Mungase SB; Verma S; Kaur S; Deka UJ; Ghosh TS; Adela R
Inflammation; 2024 Apr; ():. PubMed ID: 38676759
[TBL] [Abstract][Full Text] [Related]
9. Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis.
Pingitore P; Sasidharan K; Ekstrand M; Prill S; Lindén D; Romeo S
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30986904
[TBL] [Abstract][Full Text] [Related]
10. Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress.
Li BH; He FP; Yang X; Chen YW; Fan JG
Transl Res; 2017 Feb; 180():103-117.e4. PubMed ID: 27639593
[TBL] [Abstract][Full Text] [Related]
11. Targeting DUSP7 signaling alleviates hepatic steatosis, inflammation and oxidative stress in high fat diet (HFD)-fed mice via suppression of TAK1.
Wu L; Liu Y; Zhao Y; Li M; Guo L
Free Radic Biol Med; 2020 Jun; 153():140-158. PubMed ID: 32311490
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of adipose tissue macrophages ameliorates liver fibrosis in non-alcoholic fatty liver disease.
Martínez-Sánchez C; Bassegoda O; Deng H; Almodóvar X; Ibarzabal A; de Hollanda A; Martínez García de la Torre RA; Blaya D; Ariño S; Jiménez-Esquivel N; Aguilar-Bravo B; Vallverdú J; Montironi C; Osorio-Conles O; Fundora Y; Sánchez Moreno FJ; Gómez-Valadés AG; Aguilar-Corominas L; Soria A; Pose E; Juanola A; Cervera M; Perez M; Hernández-Gea V; Affò S; Swanson KS; Ferrer-Fàbrega J; Balibrea JM; Sancho-Bru P; Vidal J; Ginès P; Smith AM; Graupera I; Coll M
JHEP Rep; 2023 Oct; 5(10):100830. PubMed ID: 37701336
[TBL] [Abstract][Full Text] [Related]
13. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
14. FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models.
O'Farrell M; Duke G; Crowley R; Buckley D; Martins EB; Bhattacharya D; Friedman SL; Kemble G
Sci Rep; 2022 Sep; 12(1):15661. PubMed ID: 36123383
[TBL] [Abstract][Full Text] [Related]
15. Protective effects of the succinate/SUCNR1 axis on damaged hepatocytes in NAFLD.
Marsal-Beltran A; Rodríguez-Castellano A; Astiarraga B; Calvo E; Rada P; Madeira A; Rodríguez-Peña MM; Llauradó G; Núñez-Roa C; Gómez-Santos B; Maymó-Masip E; Bosch R; Frutos MD; Moreno-Navarrete JM; Ramos-Molina B; Aspichueta P; Joven J; Fernández-Real JM; Quer JC; Valverde ÁM; Pardo A; Vendrell J; Ceperuelo-Mallafré V; Fernández-Veledo S
Metabolism; 2023 Aug; 145():155630. PubMed ID: 37315889
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
[TBL] [Abstract][Full Text] [Related]
17. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
[TBL] [Abstract][Full Text] [Related]
18. The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator.
Shiragannavar VD; Sannappa Gowda NG; Puttahanumantharayappa LD; Karunakara SH; Bhat S; Prasad SK; Kumar DP; Santhekadur PK
Front Pharmacol; 2023; 14():1135952. PubMed ID: 36909161
[No Abstract] [Full Text] [Related]
19. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer.
Tsuchida T; Lee YA; Fujiwara N; Ybanez M; Allen B; Martins S; Fiel MI; Goossens N; Chou HI; Hoshida Y; Friedman SL
J Hepatol; 2018 Aug; 69(2):385-395. PubMed ID: 29572095
[TBL] [Abstract][Full Text] [Related]
20. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
